Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 3Terminated 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Lung Neoplasms 9Leukemia, Myeloid, Acute 9Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 5Prostatic Neoplasms 4Clear-cell metastatic renal cell carcinoma 4Pancreatic Neoplasms 3Melanoma 3Hematopoietic and Lymphatic System Neoplasm 3Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Anatomic Stage I Breast Cancer AJCC v8 2Adenocarcinoma Of Esophagus 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Sleep Initiation and Maintenance Disorders 1Sarcoma, Kaposi 1Rhabdomyosarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Rectal Neoplasms 1

Interventions

cemiplimab 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Actinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Gliosarcoma × Specimen Handling × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡